Vaccinex(OTC) VCNX

Vaccinex, Inc. is a biotechnology firm focused on developing specialized biological therapies for serious medical conditions. The company aims to address diseases with inadequate treatment options, including various cancers and neurodegenerative disorders.

Products and Services

• Pepinemab, a humanized monoclonal antibody in clinical trials
• VX5, targeting CXCL13 for autoimmune conditions
• Research and development in cancer and neurodegenerative diseases

Growth Outlook

• Pepinemab is in Phase 1b/2 trials for multiple cancers
• Progressing with VX5 for potential MS treatment
• Expanding pipeline to address unmet medical needs

Financial Highlights

• Recent quarterly revenue of $213,000, showing growth potential
• Trailing twelve months (TTM) revenue of $1.1 million
• Cash and cash equivalents of $1.1 million as of Q4 2024

Vaccinex, Inc. operates in the clinical stage of biotechnology, with a mission to develop therapies for conditions that currently lack effective treatments. The company's lead candidate, pepinemab, is undergoing clinical trials for various cancers, while VX5 is being evaluated for autoimmune diseases. The focus on innovative therapies positions Vaccinex to potentially capture significant market opportunities in the healthcare sector. Recent financial data indicates a quarterly revenue of $213,000, reflecting the company's ongoing efforts to generate income as it advances its clinical programs. The trailing twelve months revenue of $1.1 million suggests a growing interest in its therapeutic candidates. Additionally, the company maintains cash reserves of $1.1 million, which may support its ongoing research and development initiatives. Overall, Vaccinex, Inc. presents a compelling opportunity for investors interested in the biotechnology sector, particularly in companies dedicated to addressing critical healthcare challenges.